InvestorsHub Logo
Followers 23
Posts 1858
Boards Moderated 0
Alias Born 03/07/2014

Re: Arnold25764 post# 8200

Monday, 12/12/2022 11:55:39 AM

Monday, December 12, 2022 11:55:39 AM

Post# of 8459
Besides the anti-SARS-CoV-2 monoclonal antibodies, "Tonix's lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023."
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TNXP News